SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Klareskog L, Padyukov L, Ronnelid J, Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol 2006; 18: 6505.
  • 2
    Stastny P, Ball EJ, Dry PJ, Nunez G. The human immune response region (HLA-D) and disease susceptibility [review]. Immunol Rev 1983; 70: 11353.
  • 3
    Roitt IM, Corbett M, Festenstein H, Jaraquemada D, Papasteriadis C, Hay FC, et al. HLA-DRW4 and prognosis in rheumatoid arthritis [letter]. Lancet 1978; 1: 990.
  • 4
    Jaraquemada D, Ollier W, Awad J, Young A, Silman A, Roitt IM, et al. HLA and rheumatoid arthritis: a combined analysis of 440 British patients. Ann Rheum Dis 1986; 45: 62736.
  • 5
    De Juan MD, Belmonte I, Barado J, Martinez Laso J, Figueroa M, Arnaiz-Villena A, et al. Differential associations of HLA-DR antigens with rheumatoid arthritis (RA) in Basques: high frequency of DR1 and DR10 and lack of association with HLA-DR4 or any of its subtypes. Tissue Antigens 1994; 43: 3203.
  • 6
    Hameed K, Bowman S, Kondeatis E, Vaughan R, Gibson T. The association of HLA-DRB genes and the shared epitope with rheumatoid arthritis in Pakistan. Br J Rheumatol 1997; 36: 11848.
  • 7
    Mody GM, Hammond MG. Differences in HLA-DR association with rheumatoid arthritis among migrant Indian communities in South Africa. Br J Rheumatol 1994; 33: 4257.
  • 8
    Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A, Nunez-Roldan A. Complex associations between HLA-DRB1 genes and female rheumatoid arthritis: results from a prospective study. Hum Immunol 1999; 60: 125965.
  • 9
    Cutbush S, Chikanza IC, Biro PA, Bekker C, Stein M, Lutalo S, et al. Sequence-specific oligonucleotide typing in Shona patients with rheumatoid arthritis and healthy controls from Zimbabwe. Tissue Antigens 1993; 41: 16972.
  • 10
    Lacki JK, Wassmuth R, Korczowska I, Mackiewicz S, Muller W. Does the presence of HLA-DR B1 shared motif affect progression of the disease in rheumatoid arthritis patients? Int J Immunopathol Pharmacol 2000; 13: 839.
  • 11
    Yelamos J, Garcia-Lozano JR, Moreno I, Aguilera I, Gonzalez MF, Garcia A, et al. Association of HLA–DR4-Dw15 (DRB1*0405) and DR10 with rheumatoid arthritis in a Spanish population. Arthritis Rheum 1993; 36: 8114.
  • 12
    Salvarani C, Boiardi L, Mantovani V, Ranzi A, Cantini F, Olivieri I, et al. HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Ann Rheum Dis 1999; 58: 3038.
  • 13
    Sanchez B, Moreno I, Magarino R, Garzon M, Gonzalez MF, Garcia A, et al. HLA-DRw10 confers the highest susceptibility to rheumatoid arthritis in a Spanish population. Tissue Antigens 1990; 36: 1746.
  • 14
    Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 120513.
  • 15
    Van der Helm-van Mil AH, Huizinga TW, Schreuder GM, Breedveld FC, de Vries RR, Toes RE. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. Arthritis Rheum 2005; 52: 263744.
  • 16
    Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M, Zaller DM, et al. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med 1997; 185: 111322.
  • 17
    Rosloniec EF, Brand DD, Myers LK, Esaki Y, Whittington KB, Zaller DM, et al. Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J Immunol 1998; 160: 25738.
  • 18
    Hammer J, Takacs B, Sinigaglia F. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med 1992; 176: 100713.
  • 19
    Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J, Takacs B, et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 1993; 74: 197203.
  • 20
    Sette A, Sidney J, Oseroff C, del Guercio MF, Southwood S, Arrhenius T, et al. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol 1993; 151: 316370.
  • 21
    Eckels DD, Sell TW, Bronson SR, Johnson AH, Hartzman RJ, Lamb JR. Human helper T-cell clones that recognize different influenza hemagglutinin determinants are restricted by different HLA-D region epitopes. Immunogenetics 1984; 19: 40923.
  • 22
    Nisini R, Paroli M, Accapezzato D, Bonino F, Rosina F, Santantonio T, et al. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J Virol 1997; 71: 224151.
  • 23
    Novellino L, Renkvist N, Rini F, Mazzocchi A, Rivoltini L, Greco A, et al. Identification of a mutated receptor-like protein tyrosine phosphatase κ as a novel, class II HLA-restricted melanoma antigen. J Immunol 2003; 170: 636370.
  • 24
    De la Fuente MA, Egile C, Pereira A, Juan M, Vivanco F, Roelcke D, et al. Characterization of a monoclonal IgMK (IgMGAS) anti-Gd cold agglutinin (CA): its coexistence with a monoclonal IgG3K (IgGGAS) without CA activity that might be clonally related to IgMGAS. Blood 1994; 83: 131022.
  • 25
    Rebai N, Malissen B, Pierres M, Accolla RS, Corte G, Mawas C. Distinct HLA-DR epitopes and distinct families of HLA-Dr molecules defined by 15 monoclonal antibodies (mAb) either anti-DR or allo-anti-Iak cross-reacting with human DR molecule. I. Cross-inhibition studies of mAb cell surface fixation and differential binding of mAb to detergent-solubilized HLA molecules immobilized to a solid phase by a first mAb. Eur J Immunol 1983; 13: 10611.
  • 26
    Alvarez I, Marti M, Vazquez J, Camafeita E, Ogueta S, Lopez de Castro JA. The Cys-67 residue of HLA-B27 influences cell surface stability, peptide specificity, and T-cell antigen presentation. J Biol Chem 2001; 276: 487407.
  • 27
    Alvarez I, Carrascal M, Canals F, Muixí L, Abian J, Jaraquemada D. Analysis of the HLA class I associated peptide repertoire in a hepatocellular carcinoma cell line reveals tumor-specific peptides as putative targets for immunotherapy. Proteomics Clin Appl 2007; 1: 28698.
  • 28
    Lopez de Castro JA, Alvarez I, Marcilla M, Paradela A, Ramos M, Sesma L, et al. HLA-B27: a registry of constitutive peptide ligands. Tissue Antigens 2004; 63: 42445.
  • 29
    Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001; 17: 12367.
  • 30
    Muntasell A, Carrascal M, Serradell L, van Veelen P, Verreck F, Koning F, et al. HLA-DR4 molecules in neuroendocrine epithelial cells associate to a heterogeneous repertoire of cytoplasmic and surface self peptides. J Immunol 2002; 169: 505260.
  • 31
    Hennecke J, Wiley DC. Structure of a complex of the human α/β T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. J Exp Med 2002; 195: 57181.
  • 32
    Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368: 21521.
  • 33
    Newton-Nash DK, Eckels DD. Differential effect of polymorphism at HLA-DR1 β-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides. J Immunol 1993; 150: 181321.
  • 34
    Busch R, Hill CM, Hayball JD, Lamb JR, Rothbard JB. Effect of natural polymorphism at residue 86 of the HLA-DR β chain on peptide binding. J Immunol 1991; 147: 12928.
  • 35
    Demotz S, Barbey C, Corradin G, Amoroso A, Lanzavecchia A. The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86. Eur J Immunol 1993; 23: 42532.
  • 36
    Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997; 7: 47381.
  • 37
    Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364: 339.
  • 38
    Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc Natl Acad Sci U S A 1996; 93: 7348.
  • 39
    Rosloniec EF, Ivey RA III, Whittington KB, Kang AH, Park HW. Crystallographic structure of a rheumatoid arthritis MHC susceptibility allele, HLA-DR1 (DRB1*0101), complexed with the immunodominant determinant of human type II collagen. J Immunol 2006; 177: 388492.
  • 40
    Rosloniec EF, Whittington KB, Zaller DM, Kang AH. HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. J Immunol 2002; 168: 2539.
  • 41
    Verreck FA, van de Poel A, Drijfhout JW, Amons R, Coligan JE, Konig F. Natural peptides isolated from Gly86/Val86-containing variants of HLA-DR1, -DR11, -DR13, and -DR52. Immunogenetics 1996; 43: 3927.
  • 42
    Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA, et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992; 358: 7648.
  • 43
    Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Muller M, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A 2005; 102: 79227.
  • 44
    Kinouchi R, Kobayasi H, Sato K, Kimura S, Katagiri M. Peptide motifs of HLA-DR4/DR53 (DRB1*0405/DRB4*0101) molecules. Immunogenetics 1994; 40: 3768.
  • 45
    Friede T, Gnau V, Jung G, Keilholz W, Stevanovic S, Rammensee HG. Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides. Biochim Biophys Acta 1996; 1316: 85101.